Clinical trial / 2012
Echinacea supplementation showed borderline significantly lower respiratory symptom scores during travel compared to placebo in long-haul air travellers.
A randomised, double-blind, placebo-controlled trial assessed whether a standardised Echinacea formulation prevents respiratory and other symptoms in 175 adults on long-haul flights. Participants took Echinacea (root extract, standardised to 4.4 mg alkylamides) or placebo tablets and were surveyed before, immediately after, and 4 weeks after travel. Respiratory symptoms increased significantly during travel in both groups (P < 0.0005). However, the Echinacea group demonstrated borderline significantly lower respiratory symptom scores compared to placebo during travel (P = 0.05).
- Study type
- Randomised, double-blind, placebo-controlled trial
- Who was studied
- 175 adults travelling from Australia to America, Europe, or Africa for 1-5 weeks
- What was measured
- Upper respiratory symptoms and travel-related quality of life
THE PAPER
Randomised, double blind, placebo-controlled trial of echinacea supplementation in air travellers.
Tiralongo E, Lea RA, Wee SS, Hanna MM, Griffiths LR. Evid Based Complement Alternat Med, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.